Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis (vol 4, pg 927, 2021)
原文： 2022 年 发布于
Int Braz J Urol
40 卷 第 1 期 198-201
浏览量：229次
作者：
Laukhtina E.
Shim S. R.
Mori K.
D'Andrea D.
Soria F.
Rajwa P.
Mostafaei H.
Comperat E.
Cimadamore A.
Moschini M.
Teoh J. Y. C.
Enikeev D.
Xylinas E.
Lotan Y.
Palou J.
Gontero P.
Babjuk M.
Witjes J. A.
Kamat A. M.
Roupret M.
Shariat S. F.
Pradere B.
作者单位：
Department of Urology, Pitié Salpêtrière Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, F-75013, Paris, France
Division of Urology, Geneva University Hospitals, Geneva, Switzerland. Department of Urology, Pitié Salpêtrière Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, F-75013, Paris, France. Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain. Urology Unit, Academic Medical Centre `Santa Maria della Misericordia`, Udine, Italy. Urology Department, Hospital Clínic de Barcelona, Barcelona, Catalunya, Spain. Department of Urology, University Hospitals Leuven, Leuven, Belgium
Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain. Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. Department of Urology, Pitié Salpêtrière Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, F-75013, Paris, France. Electronic address: thomas.seisen@aphp.fr.
归属分类：
膀胱肿瘤诊断证据
DOI：
10.1016/j.ejso.2022.06.005
关键词：
Bcg
Bacillus Calmette–Guérin
Nmibc
bladder cancer
checkpoint inhibition therapy
nadofaragene firadenovec
non muscle invasive
oncolytic viruses
(1) Purpose: To assess the survival benefit for different times to adjuvant chemotherapy after a radical cystectomy. (2) Materials and Methods: We systematically searched PubMed(®), Cochrane Central(®), Scopus(®), and Web of Science(®) library databases for original articles that looked at timing to adjuvant chemotherapy after radical cystectomy. Primary endpoints were five-year survival, progression free survival, and overall survival. Available multivariable hazard ratios and corresponding 95% CIs were included in the qualitative analysis. The risk of bias was completed for nonrandomized studies. (3) Results: Using PRISMA guidelines, our electronic search resulted in a total of 1862 records. After a detailed review, we selected four studies that addressed the impact of the timing of adjuvant chemotherapy for patients who underwent radical cystectomy. (4) Conclusion: A survival benefit was seen with an earlier administration of adjuvant chemotherapy, albeit a benefit persists for delayed chemotherapy post-radical cystectomy. A safe and ethical approach at this time would be to administer adjuvant chemotherapy as early in the postoperative period as possible, given the known survival benefit of such therapy (9-11% absolute survival benefit at five years).